Pharmacogenetics of acenocoumarol in patients with extreme dose requirements
- 1 May 2010
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (5) , 1012-1017
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapyBlood, 2009
- Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of WarfarinJournal of General Internal Medicine, 2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLOS Genetics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirementBlood, 2008
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005